Orencia Outperforming Rituxan In RA, Bristol Says; Branded DTC To Start Soon
Physicians more frequently prescribe Bristol-Myers Squibb's Orencia than Genentech/Biogen Idec's Rituxan for rheumatoid arthritis, Bristol Worldwide Pharmaceuticals President Lamberto Andreotti said
You may also be interested in...
Bristol-Myers Squibb will be required to submit follow-up data from ongoing clinical trials to convert the accelerated approval of Sprycel for chronic myeloid leukemia to full approval, FDA said after clearing dasatinib June 28
Genentech/Biogen Idec are pricing Rituxan (rituximab) for rheumatoid arthritis at a lower cost for most patients than the closest comparable biologic, Bristol-Myers Squibb's Orencia (abatacept)
Bristol-Myers Squibb is launching its rheumatoid arthritis treatment Orencia (abatacept) through a sole distributor to ensure patient access while the firm works to expand its manufacturing capacity